Drug Discovery

AstraZeneca’s Tozorakimab Succeeds in Phase III COPD Trial
Management & Regulatory AstraZeneca’s Tozorakimab Succeeds in Phase III COPD Trial

Chronicobstructivepulmonarydiseaseremainsaprimarydriverofglobalmorbidityyetnearlyfiftypercentofpatientscurrentlystruggletomanagetheconditiondespiteadherencetomoderninhaledmedications. The therapeutic landscape for this debilitating respiratory condition is currently undergoing a radical

Can the Prrx1 Gene Predict Breast Cancer Metastasis?
Research & Development Can the Prrx1 Gene Predict Breast Cancer Metastasis?

The survival of a breast cancer patient often hinges on a biological mystery that takes place at the jagged, microscopic frontier of a primary tumor. For years, the medical community viewed the spread of cancer as a chaotic series of unfortunate mutations or a simple failure of the immune system to

ProteomeXchange Consortium – Review
Tech & Innovation ProteomeXchange Consortium – Review

The modern biological revolution is no longer written solely in the sequences of the genome but in the intricate, shifting patterns of proteins that define every breath and heartbeat we experience. For years, the scientific community struggled with a deluge of raw information produced by

Study Links Common Prenatal Drugs to Higher Autism Risk
Research & Development Study Links Common Prenatal Drugs to Higher Autism Risk

In the landscape of modern medicine, the intersection of maternal health and fetal neurodevelopment remains one of the most delicate frontiers. Ivan Kairatov, a distinguished biopharma expert with a profound background in research and development, brings a wealth of knowledge to this conversation,

How Can Targeted Peptides Revolutionize Arthritis Treatment?
Research & Development How Can Targeted Peptides Revolutionize Arthritis Treatment?

The progressive erosion of joint tissue in rheumatoid arthritis remains one of the most significant challenges in modern rheumatology, primarily because the condition often remains invisible until structural damage becomes irreversible. While current clinical protocols rely heavily on systemic

Can AI-Engineered Peptides Finally Defeat MRSA?
Research & Development Can AI-Engineered Peptides Finally Defeat MRSA?

Ivan Kairatov is a distinguished biopharma expert who has spent years at the intersection of technology and drug discovery, focusing on how computational innovation can solve the most pressing challenges in infectious disease. With a deep background in research and development, Kairatov has

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later